Process Of Mutation, Cell Fusion, Or Genetic Modification Patents (Class 435/440)
  • Patent number: 10358661
    Abstract: The invention provides genetically engineered microorganisms with modified hydrogenase activity and methods related thereto. Typically, the microorganisms are C1-fixing microorganisms with one or more disruptive mutations in a hydrogenase enzyme or a hydrogenase accessory enzyme. The microorganisms may have improved tolerance to toxins, such as acetylene, isocyanide, ammonium, or nitric oxide, improved production of products, such as ethanol, 2,3-butanediol, and isopropanol, and/or improved fixation of carbon, such as carbon derived from CO or CO2.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 23, 2019
    Assignee: LANZATECH NEW ZEALAND LIMITED
    Inventors: Shilpa Nagaraju, Michael Koepke
  • Patent number: 10337001
    Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: July 2, 2019
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Daniel E. Ryan, Douglas J. Dellinger, Jeffrey R. Sampson, Robert Kaiser, Joel Myerson
  • Patent number: 10267801
    Abstract: This disclosure relates to a diagnostic/prognostic assay for prostate cancer and including kits used in said assay.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: April 23, 2019
    Inventor: Ronald Alfred Laskey
  • Patent number: 10254285
    Abstract: The invention provides methods for isolating large oncosomes and determining cancer metastasis based on the presence of large oncosomes and contents of the large oncosomes in a subject in need thereof. Also provided herein are methods for treating cancer metastasis by specifically targeting contents of the large oncosomes.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 9, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dolores Di Vizio, Michael R. Freeman, Matteo Morello, Valentina R. Minciacchi
  • Patent number: 10174315
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: January 8, 2019
    Assignees: The General Hospital Corporation, Translate Bio MA, Inc.
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Patent number: 10132810
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 20, 2018
    Assignee: Nektar Therapeutics
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • Patent number: 10126301
    Abstract: The invention generally provides improved compositions and methods for detecting, diagnosing, prognosing, and monitoring multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in a subject. In particular, the invention provides methods for detecting BCMA in subjects to reliably diagnose, predict survival, or monitor multiple myeloma, chronic lymphocytic leukemia, or B-cell non-Hodgkin lymphoma in the subject.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: November 13, 2018
    Assignee: Institute for Myeloma & Bone Cancer Research
    Inventors: James R. Berenson, Haiming Chen, Eric Sanchez
  • Patent number: 10087415
    Abstract: Provided are: a cell tray provided with a concave part for supporting a cell aggregate and a hole formed on the bottom of the concave part; and a device for producing a cell structure, said device being provided with the cell tray and a puncture part passing through the cell tray and the cell aggregate, characterized in that the puncture part passes through the cell aggregate supported by the concave part until the tip thereof intrudes into the hole.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: October 2, 2018
    Assignee: CYFUSE BIOMEDICAL K.K.
    Inventors: Koji Kuchiishi, Tadashi Tamura
  • Patent number: 10081816
    Abstract: Systems and methods for transfection devices are contemplated for delivery of various complex macrostructures. Preferred systems and methods are suitable for mRNA reprogramming and genome editing and use mechanical force to induce uptake of the macrostructures in a target cell. Contemplated devices are able to achieve high throughput of transfected cells in remarkably short time that remain viable and are capable of producing colonies.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 25, 2018
    Assignee: Nant Holdings IP, LLC
    Inventor: Ting Wu
  • Patent number: 9994910
    Abstract: The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bu-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: June 12, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Charles L. Sawyers, Mercedes E. Gorre, Neil Pravin Shah, John Nicoll
  • Patent number: 9969792
    Abstract: The present invention provides methods and compositions for converting a first polypeptide into a chimeric polypeptide. The invention includes two vectors: a first vector including the sequence of the first polypeptide and a second vector including a second polypeptide. The vectors include complementary site-specific recombination motifs such that site-specific recombination between the two vectors results in the generation of a chimeric polypeptide including at least a portion of the first polypeptide and at least a portion of the second polypeptide. A site-specific recombination motif may be positioned within an intron or within a coding sequence on the first or second vector.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 15, 2018
    Assignee: AxioMx, Inc.
    Inventors: Michael Weiner, Margaret Kiss, Melissa Batonick
  • Patent number: 9952221
    Abstract: Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Expression products of identified genes are detected in patient samples, including prostate tissue, serum, semen and urine, to screen, predict and monitor prostate cancer.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: April 24, 2018
    Assignee: Health Discovery Corporation
    Inventor: Isabelle Guyon
  • Patent number: 9930871
    Abstract: Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence. Also described are genetically modified non-human animals comprising an immunoglobulin light chain locus comprising one or more but less than the wild type number of human immunoglobulin light chain variable region gene segments, which may be operably linked to a light chain constant region nucleic acid sequence. Also provided are methods for obtaining nucleic acid sequences that encode immunoglobulin light chain variable domains capable of binding an antigen in the absence of a heavy chain.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: April 3, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: John McWhirter, Cagan Gurer, Karolina A. Meagher, Lynn Macdonald, Andrew J. Murphy
  • Patent number: 9933430
    Abstract: The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia comprising: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond, thereby binding the monoclonal antibody recognizing the glycan to the free PSA bound to the anti-free PSA antibody; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determinin
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: April 3, 2018
    Assignees: HIROSAKI UNIVERSITY, SHIZUOKA PREFECTURAL UNIVERSITY CORPORATION
    Inventors: Chikara Ohyama, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Takashi Suzuki, Ilpal Jwa, Maho Yamaguchi
  • Patent number: 9884911
    Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: February 6, 2018
    Assignee: MEDIMMUNE LIMITED
    Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
  • Patent number: 9885026
    Abstract: A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualizing, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualization, transcriptional activation or repression.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: February 6, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Stan Johan Jozef Brouns, John Van Der Oost
  • Patent number: 9863949
    Abstract: Provided herein are methods directed to the prediction and early assessment of the efficacy of cancer treatment regimens, in particular in patients undergoing therapy with a DNA-damaging chemotherapeutic agent, by determining expression levels of certain proteins found to be useful as biomarkers in circulating tumor cells obtained from the patient both prior to and post-treatment.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: January 9, 2018
    Inventors: Ute Hoch, Christine Taylor Brew, Stephen David Harrison, Dennis G. Fry, Darren W. Davis
  • Patent number: 9862792
    Abstract: Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic pH, and a second block that has hydrophobic groups. This second block further has at least one unit with a group that is anionic at about physiologic pH. The described copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the copolymer is endosomolytic.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: January 9, 2018
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Danielle Benoit, Craig L. Duvall, Paul H. Johnson, Anna S. Gall
  • Patent number: 9822407
    Abstract: Unbiased, genomewide and highly sensitive methods for detecting mutations, e.g., off-target mutations, induced by engineered nucleases.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: November 21, 2017
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Patent number: 9816996
    Abstract: The present invention provides an antibody capable of specifically recognizing and detecting the highly specific cancer marker with respect to the epithelial ovarian cancer, or a fragment of the antibody. The present invention provides an anti-?1,3-N-acetylglucosaminyltransferase 3 antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,3-N-acetylglucosaminyltransferase 3 as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: November 14, 2017
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
  • Patent number: 9804163
    Abstract: The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 31, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Gildersleeve, Christopher Campbell, Oyindasola Oyelaran, James Gulley, Jeffrey Schlom
  • Patent number: 9630998
    Abstract: The present inventors have solved the crystal structure of an Escherichia coli bacterial lipocalin polypeptide, which depicts a monomeric protein. Previous crystal structures have been reported, but these appear to he inaccurate, as they predicted, e.g., a dimeric protein. The crystal structure of a bacterial lipocalin provided by the present invention leads to numerous uses. For example, the present invention provides for the design, construction and use of recombinant libraries of diversified bacterial lipocalins resulting from a bacterial lipocalin polypeptide “backbone”.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: April 25, 2017
    Assignee: Technische Universitaet Muenchen
    Inventors: Arne Skerra, Andre Schiefner
  • Patent number: 9630950
    Abstract: The present invention relates to polyamides capable of inhibiting ARE-, GRE- and ERE-mediated gene regulation in cells. The present invention also relates to polyamides capable of modulating the activity of RNA polymerase II and p53. The invention also relates to methods to treat diseases related to ARE-, GRE- and ERE-mediated gene regulation and to RNA polymerase II and p53 activity.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: April 25, 2017
    Assignee: California Institute of Technology
    Inventors: Peter B. Dervan, Nicholas G. Nickols, Claire S. Jacobs, Michelle E. Farkas, Daniel A. Harki
  • Patent number: 9533004
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Dystrophin family, in particular, by targeting natural antisense polynucleotides of Dystrophin family. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DMD family.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 3, 2017
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 9487807
    Abstract: The present invention provides methods, kits, and compositions for producing single-stranded circular DNA by PCR. In particular, hairpin primers are provided, and methods of use thereof to produce single-stranded circular DNA molecules.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: November 8, 2016
    Assignee: IBIS BIOSCIENCES, INC.
    Inventors: Mark W. Eshoo, John Picuri
  • Patent number: 9353416
    Abstract: It is intended to provide a system of predicting the postoperative prognosis in a patient with breast cancer from the viewpoint of gene expression based on the data obtained by genome-wide and comprehensive analysis on gene expression in breast cancer. Expression of human genes is comprehensively analyzed by using a DNA microarray and gene expression functions in various breast cancer conditions are compared, thereby establishing a system of predicting the postoperative prognosis of breast cancer.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: May 31, 2016
    Assignees: Mitsubishi Rayon Co., Ltd., Nippon Medical School
    Inventors: Mitsuru Emi, Masamitsu Onda, Hisaki Nagai
  • Patent number: 9334333
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: May 10, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Patent number: 9273294
    Abstract: Processes and C/D box small nucleolar RNAs (snoRNAs) for altering telomerase activity and altering telomerase length are described. The processes of the invention involve the use of C/D box snoRNAs for targeted 2?-O-methylation modification of nucleotides in a pseudoknot region of the telomerase RNA. Depending on their position, the 2?-O-methylation modifications can cause an increase in telomerase activity and subsequent telomere lengthening or a decrease in telomerase activity and subsequent telomere shortening.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: March 1, 2016
    Assignee: University of Rochester
    Inventors: Yi-Tao Yu, Chao Huang
  • Patent number: 9238813
    Abstract: Methods for affecting mRNA expression or translation through the modification of pre-mRNA or mRNA transcripts are described. In one embodiment of the methods of the present invention, the branch point adenosine of a pre-mRNA transcript is 2?-0-methylated to block splicing and subsequent expression of the protein encoded by the transcript. In another embodiment, a uridine residue in a nonsense stop codon may be modified to pseudouridine, causing the translation machinery to read through the nonsense stop codon and translate a full length protein.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: January 19, 2016
    Assignee: University of Rochester
    Inventors: Yi-Tao Yu, Xinliang Zhao
  • Patent number: 9228206
    Abstract: Disclosed is a simple and highly efficient method for introducing a gene into a target cell using a retrovirus vector. The method comprises the steps of (a) placing a liquor containing a retrovirus vector having a foreign gene carried thereon into a bag for cell culture on which a retrovirus-binding substance has been immobilized, and incubating the liquor at a temperature lower than 25° C. for 8-48 hours, thereby producing a culture bag having the retrovirus vector bound thereto, (b) adding a target cell to the culture bag that has been produced in step (a) and incubating the culture bag for 8 hours or less, and (c) flipping the culture bag upside down and incubating the culture bag. The gene introduction method is useful particularly in medicine, cell technology, gene technology, and embryologic technology.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: January 5, 2016
    Assignee: TAKARA BIO INC.
    Inventors: Katsuyuki Dodo, Naoki Saito, Hideto Chono, Junichi Mineno
  • Patent number: 9206262
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 8, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Patent number: 9206263
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: December 8, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Meagher
  • Patent number: 9023989
    Abstract: Protein-based photovoltaic cells and the manufacture and use of protein-based photovoltaic cells are described. In one embodiment, bacteriorhodopsin from Halobacterium salinarum, which undergoes structural transitions when irradiated with a given wavelength of light, is used as the protein in the protein-based photovoltaic cells. In another embodiment, mutant bacteriorhodopsin from H. salinarum is used. Exposure of the protein to sunlight causes proton transfer across a membrane resulting in the generation of an electrical charge. The protein can be oriented and/or layered on a substrate and modified by mutation to enhance transmembrane proton transfer, covalent binding to a substrate and layering. The protein-based photovoltaic cells sequentially or simultaneously generate hydrogen gas from water or salt, which also can be harnessed to produce electricity.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: May 5, 2015
    Assignee: University of Connecticut
    Inventors: Robert R. Birge, Rekha Rangarajan
  • Patent number: 9018013
    Abstract: The present invention provides compositions and methods for the genetic manipulation of Algal cells. The compositions and methods allow enhanced transfer of genetic material into Algal cells and the cloning and selection of genetically modified cells. Expression of proteins encoded by the genetic material will be enhanced by the methods and compositions of the invention.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: April 28, 2015
    Assignee: Life Technologies Corporation
    Inventors: Farzad Haerizadeh, Todd Peterson, Wen Chen, Ewa Lis
  • Patent number: 9017979
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency, mismatch tolerance, extension rate and/or tolerance of RT and polymerase inhibitors relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: April 28, 2015
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Fred Reichert, Joseph San Filippo, Rachel Shahinian, Shawn Suko
  • Publication number: 20150110944
    Abstract: The invention relates to the field of Citrullus lanatus, in particular to a new variety of watermelon designated NUN 7201 WMW as well as plants, seeds and watermelon fruits thereof.
    Type: Application
    Filed: January 6, 2015
    Publication date: April 23, 2015
    Inventor: Erik de Groot
  • Patent number: 9013864
    Abstract: A device includes: a first component and a second component coupled to one another by a pivot member and being movable relative to one another between an open position in which the first component and the second component are in the same plane and a folded position; a first slider coupled to the first component and a second slider coupled to the second component; and a flexible membrane coupled to the first slider and the second slider, the flexible membrane being exposed in the folded position; wherein the first component and the second component are coupled to one another to maintain the flexible membrane at a constant length when the flexible membrane is moved between the open position and the folded position.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: April 21, 2015
    Assignee: BlackBerry Limited
    Inventors: Jason Tyler Griffin, Martin Philip Riddiford, Daniel Jordan Kayser
  • Patent number: 9011948
    Abstract: Process for producing a dairy product by adding a lactase to a dairy product which contains lactose, the lactase added having less than 40 units arylsulfatase activity per NLU of lactase activity.
    Type: Grant
    Filed: November 28, 2006
    Date of Patent: April 21, 2015
    Assignee: DSM IP Assets B.V.
    Inventors: Petrus Jacobus Theodorus Dekker, Luppo Edens, Maximiliaan Peter Marie De Swaaf, Albertus Alard Van Dijk
  • Patent number: 9005948
    Abstract: The present invention provides a novel endoglucanase nucleic acid sequence, designated egl7, and the corresponding EGVII amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding EGVII, recombinant EGVII proteins and methods for producing the same.
    Type: Grant
    Filed: January 20, 2014
    Date of Patent: April 14, 2015
    Assignee: Danisco US Inc.
    Inventors: Nigel Dunn-Coleman, Frits Goedegebuur, Michael Ward, Jian Yao
  • Patent number: 9006193
    Abstract: Provided herein are polymeric carriers suitable for the delivery of polynucleotides (e.g. oligonucleotides) and/or other therapeutic agents into a living cell.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: April 14, 2015
    Assignees: University of Washington, PhaseRx, Inc.
    Inventors: Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Craig L. Duvall, Danielle Benoit, Robert W. Overell, Paul H. Johnson, Anna S. Gall, Mary G. Prieve, Amber E. E. Paschal, Charbel Diab, Priyadarsi De
  • Patent number: 9005952
    Abstract: The present invention relates to a microorganism producing L-methionine precursor, O-acetylhomoserine, and a method of producing L-methionine precursor using the microorganism.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: April 14, 2015
    Assignee: CJ Cheiljedang Corporation
    Inventors: Chul Ha Kim, So Young Kim, Young Uk Shin, Hye Won Um, Jin Sook Chang, Young Wook Cho, Han Jin Lee, In Kyung Heo, Chang Il Seo, Kwang Ho Na
  • Patent number: 9005935
    Abstract: The present invention provides new compositions for transposase-mediated fragmenting and tagging DNA targets. The invention relates to the surprising discovery that use of manganese ions (Mn2+) in transposase reactions improves the transposase reaction. It also relates to the surprising discovery that Mg2+ ions can be used in a transposase reaction with wild-type and/or engineered transposases at levels much higher than previously thought. The invention provides for the use of naturally-occurring transposases in in vitro reactions, as well as improved schemes for cleaving, tagging, and amplifying target DNA.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: April 14, 2015
    Assignee: Agilent Technologies, Inc.
    Inventor: Alexander S. Belyaev
  • Patent number: 9005947
    Abstract: The present invention provides a novel ?-glucosidase nucleic acid sequence, designated bgl7, and the corresponding BGL7 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding BGL7, recombinant BGL7 proteins and methods for producing the same.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: April 14, 2015
    Assignee: Danisco US Inc.
    Inventors: Nigel Dunn-Coleman, Michael Ward
  • Patent number: 9006406
    Abstract: An epidermal growth factor receptor (EGFR)-homing vector comprising a double-stranded RNA (dsRNA) molecule with an EGFR-binding peptide or polypeptide, is disclosed for use in combination with immune cells for treatment of cancer overexpressing EGFR.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: April 14, 2015
    Inventors: Alexander Levitzki, Alexei Shir
  • Patent number: 9005973
    Abstract: Disclosed herein are donor molecules comprising single-stranded complementary regions flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: April 14, 2015
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Gregory J. Cost, Dmitry M. Guschin, Fyodor Urnov
  • Patent number: 8999714
    Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of stem cells. Certain embodiments disclosed herein include, but are not limited to, methods of modifying stem cells, or methods of administering modified stem cells to at least one biological tissue.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: April 7, 2015
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Lowell L. Wood, Jr.
  • Patent number: 8999637
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: April 7, 2015
    Assignee: Bavarian Nordic A/S
    Inventor: Robin Steigerwald
  • Patent number: 8993327
    Abstract: Systems and methods are described for parallel macromolecular delivery and biochemical/electrochemical interface to whole cells employing carbon nanostructures including nanofibers and nanotubes. A method includes providing a first material on at least a first portion of a first surface of a first tip of a first elongated carbon nanostructure; providing a second material on at least a second portion of a second surface of a second tip of a second elongated carbon nanostructure, the second elongated carbon nanostructure coupled to, and substantially parallel to, the first elongated carbon nanostructure; and penetrating a boundary of a biological sample with at least one member selected from the group consisting of the first tip and the second tip.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: March 31, 2015
    Assignee: UT-Battelle, LLC
    Inventors: Timothy E. McKnight, Anatoli V. Melechko, Guy D. Griffin, Michael A. Guillorn, Vladimir L. Merkulov, Michael L. Simpson
  • Patent number: 8993301
    Abstract: The present invention relates to novel expression cassettes and expression vectors, comprising three nucleic acid sequences for araA, araB and araD, each coding for a polypeptide of an L-arabinose metabolic pathway, in particular, a bacterial L-arabinose metabolic pathway. The invention particularly relates to expression cassettes and expression vectors, comprising codon-optimized nucleic acid sequences for araA, araB and araD. The invention further relates to host cells, in particular modified yeast strains containing the expression cassettes or expression vectors and expressing the polypeptides for the L-arabinose metabolic pathway, in particular, for the bacterial L-arabinose metabolic pathway. When using these modified host cells, arabinose is more effectively fermented by these cells, in particular into ethanol. The present invention is therefore relevant, inter alia, in connection with the production of biochemicals from biomass, such as bioethanol for example.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: March 31, 2015
    Assignee: Butalco GmbH
    Inventors: Eckhard Boles, Beate Rother
  • Patent number: 8993296
    Abstract: An object of the present invention is to provide enzymes associated with equol synthesis, genes coding such enzymes, and a process for producing equol and its intermediates using the enzymes and genes. The present invention provides a dihydrodaidzein synthesizing enzyme, tetrahydrodaidzein synthesizing enzyme, equol synthesizing enzyme, and genes coding these enzymes. The present invention also provides a process for synthesizing dihydrodaidzein, tetrahydrodaidzein, and/or equol using these enzymes.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 31, 2015
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Yoshikazu Shimada, Setsuko Yasuda, Masayuki Takahashi, Takashi Hayashi, Norihiro Miyazawa, Yasuhiro Abiru, Tadaaki Ohtani, Ikutaro Sato